1. Pfizer/BioNTech COVID-19 vaccine
Product name: COMIRNATY (BNT162b2 [mRNA]) COVID-19 VACCINE.
On January 25, 2021, Prime Minister Scott Morrison announced that the Therapeutic Goods Administration (TGA) had provisionally approved the BioPfizNTech COVID-19 vaccine for use in Australia. The TGA provisional COVID vaccine approval is for individuals 16 years of age and older.
Pfizer’s COVID vaccine used mRNA technology. Such vaccines deliver mRNA, coated in lipid (fat), into cells. Once inside, your body uses instructions in the mRNA to make SARS-CoV-2 spike proteins.
Here is a new flyer from the Physicians for Informed Consent with information on the Pfizer/BioNTech COVID-19 vaccine
Downloadable PDF here
Should we use the word ‘vaccine’ for this new technology?
A vaccine for this is a misnomer. It is not a vaccine. It is an intermediary product which leads to the production of a protein that generates a so-called “vaccine”… and it is genetic engineering that has never been tested out in human beings before. And if it causes a problem a year, two years, five years down the line, and it has already been given to billions of people worldwide, it’s too late. You can’t take it out, you can’t switch it off, you can’t stop it. It’s in there.— Andrew Wakefield, MD
For more information about the mRNA technology have a listen to Kathy Scarborough from Vaccination Information SA who was interviewed by Matthew Pantellis on 5AA radio Adelaide.
2. AstraZeneca COVID-19 Vaccine
On February 16, 2021, the Therapeutic Goods Administration (TGA) granted provisional approval to AstraZeneca Pty Ltd for its COVID-19 vaccine, making it the second COVID-19 vaccine to receive regulatory approval in Australia.
The TGA does not conduct its own vaccine trials but depends on data obtained from the U.S Food and Drug Administration (FDA).
Explaining how the vaccine works, study lead author Professor Andrew Pollard, University of Oxford, UK, says: “The new vaccine is a chimpanzee adenovirus viral vector (ChAdOx1) vaccine that expresses the SARS-CoV-2 spike protein. It uses a common cold virus (adenovirus) that infects chimpanzees, which has been weakened so that it can’t cause any disease in humans, and is genetically modified to code for the spike protein of the human SARS-CoV-2 virus. This means that when the adenovirus enters vaccinated people’s cells it also delivers the spike protein genetic code. This causes these people’s cells to produce the spike protein, and helps teach the immune system to recognise the SARS-CoV-2 virus.”
It is not known whether these experimental vaccines have ever prevented transmission or reduced the number of deaths from the ‘virus’. The decision to approve them has been made of the basis of short term efficacy and safety data.
COVID-19 Vaccine rollout begins in Australia
Sunday February 21, 2021
After a year of forced isolation, quarantine and lockdown, mandatory mask wearing and societal upheaval, the COVID vaccine rollout began. The rollout of the BioPfizNTech COVID-19 is to be carried out in phases with the first phase including quarantine and border workers, frontline health care workers and aged care and disability care staff.
3. The Moderna COVID-19 vaccine
Like the Pfizer vaccine, Moderna’s mRNA-1273 uses synthetic messenger RNA (mRNA) technology — a type of genetic engineering never before used, much less proven safe, in vaccine production.
The Moderna COVID-19 vaccine (mRNA-1273) is made from synthetic genetic material that is immersed in fatty substances, including cholesterol and polyethylene glycol (PEG). More specifically, modified RNA molecules that encode for a mutated spike (S) protein antigen of the SARS-CoV-2 virus, the virus that can cause COVID-19, are immersed in lipid nanoparticles. The drug is administered in two intramuscular 100 mcg doses, 28 days apart.
From Moderna’s website:
Our Operating System
Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the “program” or “app” is our mRNA drug – the unique mRNA sequence that codes for a protein
Does Moderna prevent hospitalisations or death?
Since only 10 hospitalized cases and one death of COVID-19 were observed, the clinical trial did not have enough statistical power to accurately measure the vaccine’s ability to prevent hospitalizations or deaths from COVID-19. The vaccine may be only 13% effective against hospitalized COVID-19 cases.
The FDA states,
A larger number of individuals at high risk of COVID-19 and higher attack rates would be needed to confirm efficacy of the vaccine against mortality.
The Moderna COVID-19 vaccine obtained emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) on Dec. 18, 2020, and is currently investigational.
Australia is buying 25 million doses of the Moderna vaccine. Health Minister Greg Hunt on May 13, 2021 confirmed the deal, which he said would see 1 million doses arrive by September and 9 million doses by December.
TGA provisionally approves Moderna’s COVID-19 vaccine
On 9 August 2021, the Therapeutic Goods Administration (TGA), part of the Department of Health, granted provisional approval to Moderna Australia Pty Ltd for its COVID-19 vaccine – Spikevax (elasomeran) – making it the fourth COVID-19 vaccine to receive regulatory approval in Australia. This messenger RNA (mRNA) vaccine is provisionally approved and included in the Australian Register of Therapeutic Goods (ARTG) for active immunisation to prevent coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older. It is recommended that the vaccine is given in two doses that are administered 28 days apart.
Data to support the use of Moderna’s COVID-19 vaccine in adolescents aged 12 to 17 years are currently under evaluation and no specific concerns have been identified to date. The TGA’s decision on use in this age group will be announced separately.
On 3 September 2021 the Therapeutic Goods Administration (TGA) granted provisional approval to Moderna Australia Pty Ltd for the use of its COVID-19 vaccine—SPIKEVAX (elasomeran)—in individuals aged 12 years and older.
Scandinavians suspend Moderna for young people
On October 7 2021, Scandinavian authorities suspended or discouraged the use of Moderna’s COVID-19 vaccine in young people because of an increased risk of heart inflammation, a very rare side effect associated with the shot. Sweden suspended the use of Moderna for those recipients under 30, Denmark said those under 18 won’t be offered the Swiss-made vaccine, and Norway urged those under 30 to get the Pfizer vaccine instead. All three countries based their decision on an unpublished study with Sweden’s Public Health Agency saying that it signals “an increased risk of side effects such as inflammation of the heart muscle or the pericardium” — the double-walled sac containing the heart and the roots of the main vessels.
4. TGA provisionally approves the third Covid-19 vaccine – Janssen-Cilag Pty Ltd (known as Johnson & Johnson overseas)
This viral vector vaccine is provisionally approved and included in the Australian Register of Therapeutic Goods (ARTG) for the active immunisation for the prevention of coronavirus disease-2019 (COVID-19) in adults greater than or equal to 18 years of age. The official recommendation is for this vaccine to be given in a single dose. The Janssen vaccine is not included in Australia’s COVID-19 vaccination program.
5. TGA provisionally approves Novavax (Biocelect Pty Ltd’s) COVID-19 vaccine NUVAXOVID
On January 20 2022, the Therapeutic Goods Administration (TGA) granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) for its COVID-19 vaccine, NUVAXOVID. This is the first protein COVID-19 vaccine to receive regulatory approval in Australia.
This protein vaccine is provisionally approved and included in the Australian Register of Therapeutic Goods (ARTG) for active immunisation to prevent COVID-19 in individuals 18 years of age and older. It is recommended that the vaccine is given in 2 doses administered 3 weeks apart.
Aborted human foetal cells in COVID vaccines
The COVID-19 Vaccine AstraZeneca (ChAdOx1-S) was produced in genetically modified human embryonic kidney cells. The cells are from aborted tissue obtained in the 1970s.
Astrazeneca’s shot is not the only COVID-19 vaccine to use aborted human cells in production. During the manufacture of their COVID-19 vaccines, Pfizer, Moderna and Johnson & Johnson also used specialised cells originally derived from aborted foetal tissue.
See: Guidance on Getting the COVID-19 Vaccine
When the issue of aborted foetal cell lines arises the debate tends to revolve around the moral and ethical aspects of the use of aborted foetuses. However the use of such tissue can also result in damage to human health.
According to expert Dr Theresa Deisher: The adverse health effects of using of human foetal cell lines arise because:
Contaminating human DNA in these vaccines has the potential to trigger auto- immune responses and also the potential to become incorporated into our own genes, a process called homologous recombination
There are high levels of contaminants left in the vaccine. When the vaccine is manufactured using a chicken cell there are chicken contaminants and we recognise this as non human and it is eliminated from our bodies. However when the cell line used is from human foetal material this is human and we don’t eliminate the same species fragments from our body.
See: Testimony Submitted by: Dr. Theresa A. Deisher
See: Aborted fetal cells and vaccines – a scandal much bigger than Pfizer’s whistleblower ever imagined
The fetal cells referred to in Pfizer’s emails were HEK293T cells, obtained from the kidney cells of a female fetus in 1973., In reality, all the currently authorized COVID-19 vaccines are made using aborted fetal cells, including Moderna’s. Moderna also used HEK293T cells in their proof-of-concept tests to see if the genetic instructions contained in these vaccines would be effectively taken up and produce the required spike protein.
Johnson and Johnson used both the PER.C6 cell line (derived from human embryonic retinal cells, originally from the retinal tissue of an 18-week-old fetus aborted in 1985) and the HEK293T cell line, to produce and assay (respectively) their Janssen adenovirus vaccine.
AstraZeneca used the HEK293T cells to develop theirs, as did two other companies that have had their vaccines approved, CanSino Biologics and Gamaleya Research Institute (Sputnik V vaccine).
The use of aborted fetal cells in vaccine production has been going on for over 50 years, starting in the mid-to late 1970s. Antigens for several childhood vaccines are grown in aborted fetal cell lines MRC-5 and WI-38. These cell lines are found in the vaccines and are included in CDC’s vaccine excipient list as well as Johns Hopkins Institute for Vaccine Safety website (top and bottom images respectively).
Vaccine injury reporting
If you believe you or your child has suffered an adverse reaction to any vaccination, please fill in the form at VaxxTracker, VaxxTracker Global Vaccination Reporting.
You can also report directly to Australia’s Therapeutic Goods Administration (TGA) after filling in the details at VaxxTracker above.
Here is the link to TGA site AEMS Online
TGA’s COVID-19 vaccine weekly safety report
TGA’s Database of Adverse Event Notifications
COVID-19 Vaccine Injury
Vaccine Refusal Forms
This is a link to a new page where you can find templates of letters to give to employers who insist on COVID-19 and Influenza jabs.